Tegretol Therapeutic Dose for Epilepsy
For epilepsy, start Tegretol (carbamazepine) at 200 mg twice daily in adults and children over 12 years, or 100 mg twice daily in children 6-12 years, with gradual weekly titration to maintenance doses of 800-1200 mg/day in adults and 400-800 mg/day in children 6-12 years. 1
Adult Dosing (≥12 years)
Initial dose: 200 mg twice daily (400 mg/day total) 1
Titration: Increase by up to 200 mg/day at weekly intervals until optimal seizure control is achieved 1
Maintenance dose:
- Typically 800-1200 mg/day 1
- Maximum 1000 mg/day for ages 12-15 years 1
- Maximum 1200 mg/day for patients >15 years 1
- Rarely, doses up to 1600 mg/day have been used in adults 1
Therapeutic blood level: 4-8 mcg/mL 2
Pediatric Dosing
Children 6-12 years:
Initial dose: 100 mg twice daily (200 mg/day total) 1
Titration: Increase by up to 100 mg/day at weekly intervals 1
Maintenance dose: 400-800 mg/day (maximum 1000 mg/day) 1
Children <6 years:
Initial dose: 10-20 mg/kg/day divided into 2-3 doses 1
Titration: Increase weekly to achieve optimal response 1
Maintenance dose: Typically below 35 mg/kg/day 1
Important caveat: No safety data exists for doses above 35 mg/kg/24 hours in children 1
Critical Dosing Principles
Start low, go slow: A gradual titration approach minimizes adverse effects, particularly dizziness, ataxia, and diplopia 1. The FDA label explicitly recommends "a low initial daily dosage with a gradual increase" 1.
Formulation considerations:
- Tegretol suspension produces higher peak levels than tablets at the same dose, requiring lower starting doses (e.g., ½ teaspoon four times daily for children 6-12 years) 1
- Tegretol-XR (extended-release) allows twice-daily dosing and may improve compliance 1
- Take all formulations with meals 1
Monitoring requirements:
- Measure plasma levels if seizure control is inadequate to confirm therapeutic range (4-12 mcg/mL) 1
- Monitor complete blood count and liver enzymes regularly due to risk of leukopenia and hepatotoxicity 2
- Screen for HLA-B*15:02 allele before initiating therapy in Han Chinese populations to reduce risk of Stevens-Johnson syndrome/toxic epidermal necrolysis 3
Evidence Quality and Context
The dosing recommendations are derived from FDA-approved labeling 1, which represents the highest-quality prescribing guidance. WHO guidelines from 2011 support carbamazepine as first-line monotherapy for convulsive epilepsy, particularly for partial onset seizures 4. A 2004 American Academy of Neurology/American Epilepsy Society guideline confirms carbamazepine's efficacy in refractory partial epilepsy as adjunctive therapy in both adults and children 5.
Common pitfall: Children eliminate carbamazepine more rapidly than adults and often require higher mg/kg doses 6. The active metabolite carbamazepine-10,11-epoxide accumulates more in children, potentially causing neurotoxicity even with therapeutic parent drug levels 6.
Combination therapy: When adding carbamazepine to existing antiepileptic drugs, introduce it gradually while maintaining or slowly reducing other agents—except phenytoin, which may require dose increases due to drug interactions 1.